HC Wainwright Lowers Earnings Estimates for ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) – Research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for ADC Therapeutics in a research report issued to clients and investors on Thursday, October 16th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.40) per share for the quarter, down from their prior forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics’ Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.62) EPS.

ADC Therapeutics (NYSE:ADCT) last announced its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The business had revenue of $18.84 million during the quarter, compared to analyst estimates of $17.82 million.

Several other equities research analysts have also recently commented on ADCT. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price target on shares of ADC Therapeutics in a report on Wednesday, August 13th. Wall Street Zen lowered ADC Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

ADC Therapeutics Stock Performance

NYSE:ADCT opened at $4.28 on Monday. ADC Therapeutics has a one year low of $1.05 and a one year high of $4.74. The stock has a market cap of $481.50 million, a PE ratio of -2.73 and a beta of 1.99. The stock has a 50 day moving average price of $3.58 and a 200 day moving average price of $2.81.

Institutional Investors Weigh In On ADC Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ADCT. Nantahala Capital Management LLC purchased a new position in shares of ADC Therapeutics during the 2nd quarter worth $6,074,000. Bank of America Corp DE lifted its stake in shares of ADC Therapeutics by 22.1% during the 2nd quarter. Bank of America Corp DE now owns 2,199,059 shares of the company’s stock worth $5,893,000 after purchasing an additional 397,905 shares during the period. Corient Private Wealth LLC purchased a new position in shares of ADC Therapeutics during the 2nd quarter worth $959,000. Stempoint Capital LP purchased a new position in shares of ADC Therapeutics during the 2nd quarter worth $759,000. Finally, Panagora Asset Management Inc. increased its holdings in shares of ADC Therapeutics by 400.8% during the 2nd quarter. Panagora Asset Management Inc. now owns 271,359 shares of the company’s stock worth $727,000 after buying an additional 217,173 shares during the last quarter. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.